drugset / Trial / NCT04038411
PD-1 Antibody, Chidamide, Lenalidomide and Etoposide for Relapsed or Refractory NK/T Cell Lymphoma
NaSingle-groupOpen-labelTreatment
Summary
To observe the safety, tolerability and clinical effects of PD-1 Antibody, Chidamide, Lenalidomide and Etoposide in Relapsed or Refractory NK/T cell Lymphoma.
Timeline
- Start
- 2019-04-01
- Primary completion
- 2021-04-01
- Completion
- 2022-04-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Etoposide | Small molecule | 100 mg/m2 | — |
| Subject | Lenalidomide | Other / unclassified | 25 mg | — |
| Subject | Tucidinostat | Small molecule | 20 mg | — |